Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Operating Leases (2019 - 2025)

Cardiff Oncology (CRDF) has disclosed Operating Leases for 7 consecutive years, with $102000.0 as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 87.45% to $102000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $102000.0 through Dec 2025, down 87.45% year-over-year, with the annual reading at $102000.0 for FY2025, 87.45% down from the prior year.
  • Operating Leases hit $102000.0 in Q4 2025 for Cardiff Oncology, down from $284000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $3.1 million in Q4 2021 to a low of $6000.0 in Q2 2021.
  • Historically, Operating Leases has averaged $1.4 million across 5 years, with a median of $1.4 million in 2023.
  • Biggest five-year swings in Operating Leases: plummeted 98.6% in 2021 and later skyrocketed 38333.33% in 2022.
  • Year by year, Operating Leases stood at $3.1 million in 2021, then dropped by 12.95% to $2.7 million in 2022, then crashed by 46.3% to $1.5 million in 2023, then tumbled by 44.24% to $813000.0 in 2024, then plummeted by 87.45% to $102000.0 in 2025.
  • Business Quant data shows Operating Leases for CRDF at $102000.0 in Q4 2025, $284000.0 in Q3 2025, and $464000.0 in Q2 2025.